<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389400</url>
  </required_header>
  <id_info>
    <org_study_id>ALCH-MA-001</org_study_id>
    <nct_id>NCT02389400</nct_id>
  </id_info>
  <brief_title>Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis</brief_title>
  <acronym>MAALCH</acronym>
  <official_title>Efficacy and Tolerance of Combination Chemotherapy With Methotrexate and Cytosine Arabinoside in Newly Diagnosed Adult With Langerhans Cell Histiocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Type: Interventional

      Study Design:

      Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking:
      Open Label Primary Purpose: Treatment purpose: This single arm clinical trial is studying
      efficacy and tolerance of combination chemotherapy with methotrexate and cytosine arabinoside
      in newly diagnosed adult with Langerhans cell histiocytosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single arm clinical trial is studying efficacy and tolerance of combination chemotherapy
      with methotrexate and cytosine arabinoside in newly diagnosed adult with Langerhans cell
      histiocytosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Langerhans Cell Histiocytosis</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methotrexate,1g/m2,iv.d1 cytosine arabinoside,0.1g/m2,iv.,d1-5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Single Group Assignment</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.DISEASE CHARACTERISTICS:

          -  Histopathologically confirmed diagnosis of Langerhans cell histiocytosis according to
             the criteria defined by the Histiocyte Society

          -  Demonstration of CD1a antigenic determinants on the surface of lesional cells (by
             immunocytology or immunohistology) or Birbeck granules in lesional cells by electron
             microscopy

          -  Considered at risk or low risk according to the following criteria:

               -  Multi-system at risk disease, defined as involvement of one or more risk organs
                  (i.e., hematopoietic system, liver, spleen, or lungs)

                  1.No single-system lung involvement

               -  Multi-system low-risk disease

                  1.Multiple organs involved but without involvement of risk organs

               -  Single-system disease 1.Multifocal bone disease (i.e., lesions in 2 or more
                  different bones) 2.Localized special site involvement, such as CNS-risk lesions
                  with intracranial soft tissue extension or vertebral lesions with intraspinal
                  soft tissue extension 3.Vault lesions are not regarded as CNS-risk lesions
                  2.PATIENT CHARACTERISTICS:

                    1. Not pregnant or nursing

                    2. Negative pregnancy test

                    3. Fertile patients must use effective contraception 3.PRIOR CONCURRENT
                       THERAPY:

                    1. No prior treatment for Langerhans cell histiocytosis

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>minghui Duan, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>minghui Duan, Dr.</last_name>
    <phone>69155549</phone>
    <email>mhduan@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking union medical college hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>minghui Duan, Dr.</last_name>
      <phone>69155549</phone>
      <email>mhduan@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult with Langerhans cell histiocytosis</keyword>
  <keyword>newly diagnosed</keyword>
  <keyword>methotrexate</keyword>
  <keyword>cytosine arabinoside</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

